Skip to main content

Table 2 FA score, sociodemographic characteristics, and risk factors

From: Fatigue in breast cancer patients on chemotherapy: a cross-sectional study exploring clinical, biological, and genetic factors

Characteristic (n = 67) Mean (SD) Mean rank p-value
Nationality
 Lebanese (n = 60) 41.11 (32.24) 33.40 0.452
 Non-Lebanese (n = 7) 50.79 (31.98) 39.14
Marital status
 Non married (n = 9) 35.80 (32.29) 30.22 0.524
 Married (n = 58) 43.10 (32.24) 34.59
Education level
 Primary (n = 9) 28.40 (24.29) 24.89 0.097
 Secondary (n = 41) 48.51 (31.70) 36.76
 University (n = 15) 34.07 (34.24) 27.60
Socioeconomic level
 Low (n = 3) 18.52 (16.97) 18.83 0.177
 Middle (n = 58) 44.44 (32.58) 35.07
 High (n = 5) 24.44 (26.53) 24.10
Professional activity
 Yes (n = 22) 48.48 (34.55) 37.55 0.289
 No (n = 45) 39.01 (30.76) 32.27
Alcohol
 No (n = 59) 43.13 (31.36) 34.64 0.460
 Yes (n = 8) 34.72 (38.69) 29.31
Tobacco
 No (n = 45) 45.43 (31.14) 36.01 0.353
 Yes (n = 19) 37.42 (33.58) 31.11
 Previous smoker (n = 3) 22.22 (38.49) 22.17
Allergy
 No (n = 62) 39.96 (31.46) 32.77 0.065
 Yes (n = 5) 68.89 (30.83) 49.20
Dyslipidemia
 No (n = 56) 40.08 (31.90) 32.85 0.266
 Yes (n = 11) 52.53 (32.62) 39.86
Diabetes
 No (n = 62) 42.11 (33.19) 33.89 0.865
 Yes (n = 5) 42.22 (14.49) 35.40
Hypertension
 No (n = 50) 44.00 (32.53) 35.20 0.379
 Yes (n = 17) 36.60 (31.12) 30.47
Oral antidiabetics
 No (n = 62) 42.11 (33.19) 33.89 0.865
 Yes (n = 5) 42.22 (14.49) 35.40
Antihypertensive drugs
 No (n = 52) 42.52 (32.76) 34.31 0.806
 Yes (n = 15) 40.74 (30.77) 32.93
Dyslipidemia treatment
 No (n = 57) 39.38 (32.06) 32.40 0.103
 Yes (n = 10) 57.78 (39.07) 43.10
Antidepressant treatment
 No (n = 59) 41.05 (31.17) 33.47 0.542
 Yes (n = 8) 50.00 (39.84) 37.88
Antipsychotic treatment
 No (n = 63) 40.56 (30.80) 33.21 0.178
 Yes (n = 4) 66.67 (47.14) 46.50
Neurogenic pain treatment
 No (n = 64) 40.45 (31.14) 33.16 0.095
 Yes (n = 3) 77.78 (38.49) 52.00
Notable treatmenta
 No (n = 60) 40.86 (32.52) 32.26 0.122
 Yes (n = 7) 58.73 (21.96) 43.93
Metastasis
 No (n = 60) 38.70 (31.39) 31.93 0.010
 Yesb (n = 7) 71.43 (23.00) 51.71
Metastasis type    0.021
 No (n = 60) 38.70 (31.39) 31.93 Ref
 Bone (n = 5) 80.00 (18.26) 56.30 0.011
 Pulmonary (n = 2) 50.00 (23.57) 40.25 0.945
Chemotherapy type    0.005
 Palliative (n = 7) 71.43 (23.00) 50.71 Ref
 Adjuvant (n = 44) 34.63 (31.16) 28.47 0.010
 Neoadjuvant (n = 16) 52.08 (28.60) 39.50 0.332
Cyclophosphamide treatmentc
 No (n = 36) 49.38 (31.02) 38.13 0.057
 Yes (n = 31) 33.69 (31.75) 29.21
Capecitabine treatmentc
 No (n = 62) 39.07 (31.09) 32.20 0.007
 Yes (n = 5) 80.00 (18.26) 56.30
  1. Numbers in bold are significant results (p < 0.05)
  2. aThese treatments include benzodiazepines (alprazolam, bromazepam, clonazepam, lorazepam), opioids (tramadol and codeine) and zolpidem
  3. bPatients with metastasis were not considered as having a relapsed breast cancer (thus not excluded) because they had a primary diagnosis of metastatic breast cancer
  4. cOther treatment types did not give significant results